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Drug-resistant tuberculosis (TB), one of the leading causes of death worldwide, arises mainly from 
spontaneous mutations in the genome of Mycobacterium tuberculosis. There is an urgent need to 
understand the mechanisms by which the mutations confer resistance in order to identify new drug 
targets and to design new drugs. Previous studies have reported numerous mutations that confer 
resistance to anti-TB drugs, but there has been little systematic analysis to understand their genetic 
background and the potential impacts on the drug target stability and/or interactions. Here, we 
report the analysis of whole-genome sequence data for 98 clinical M. tuberculosis isolates from a city 
in southern India. The collection was screened for phenotypic resistance and sequenced to mine the 
genetic mutations conferring resistance to isoniazid and rifampicin. The most frequent mutation 
among isoniazid and rifampicin isolates was S315T in katG and S450L in rpoB respectively. The impacts 
of mutations on protein stability, protein-protein interactions and protein-ligand interactions were 
analysed using both statistical and machine-learning approaches. Drug-resistant mutations were 
predicted not only to target active sites in an orthosteric manner, but also to act through allosteric 
mechanisms arising from distant sites, sometimes at the protein-protein interface.
Tuberculosis (TB) caused an estimated 1.3 million deaths worldwide in 2016 (WHO Global Tuberculosis 
Report, 2017). The major challenge in the treatment of tuberculosis is the emergence of drug-resistant 
Mycobacterium tuberculosis1. The drugs available for tuberculosis treatment are categorised into first-line (iso-
niazid (INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB) and streptomycin (STR)) and second 
line (including fluoroquinolones, thioamides, cycloserine and the injectable aminoglycosides). Rising rates of 
multi-drug-resistant tuberculosis (MDR-TB, defined as resistance to INH and RIF), are of immense concern for 
TB control worldwide. Extended treatment is required with multiple drugs that have a higher rate of side effects 
but limited rate of treatment success (Gygli et al.2). India accounts for the highest burden of tuberculosis globally 
and also ranks top among the countries for MDR-TB cases (WHO Global Tuberculosis Report, 2017).
Drug resistance arises mainly from spontaneous mutations in the bacterial genome. Resistance to first-line 
anti-TB drugs has been linked to mutations in katG3 and inhA4 for INH resistance; rpoB for RIF resistance5; embB 
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for EMB resistance6; pncA for PZA resistance7,8 and rpsL and rrs for STR resistance9,10. Several large scale whole 
genomic studies have identified a catalogue of resistance-associated mutations11–16. Molecular methods such as 
Xpert MTB/RIF17 and Line Probe Assay (Cepheid, Sunnyvale, CA, USA) rely on these genetic determinants to 
identify drug-resistance. The predictive accuracies of known mutations for INH and RIF are comparable to the 
current gold standard of phenotypic drug susceptibility tests(DSTs), but vary for other drugs18.
Understanding and tackling drug resistance may be informed by an understanding of bacterial population 
structure. Fenner et al. (2012) showed that lineage was associated with particular mutations and variable levels 
of drug resistance, and suggested a role for epistatic interactions between mutations and genetic background 
in resistant strains19. In addition, some lineages such as L2 (Beijing strains) have an increased frequency of 
drug resistance20. India is notable for having a predominance of M. tuberculosis lineage 1 in the South and lin-
eage 3 in the North21. The contributions of these lineages in worldwide studies have been limited compared to 
globally-dominant lineages 2 and 4. Recently, Manson et al. (2017) reported that known mutations for INH 
and RIF accounted for only 72% of resistance among strains from Chennai, India, necessitating more studies to 
catalogue resistance-associated mutations22. Therefore, studies are needed to understand the epidemiology and 
generate a comprehensive list of resistance-conferring mutations. Since then the effects of mutations have been 
reported for isolates representing the global diversity arising from four lineages of M. tuberculosis23.
The gene mutations in M. tuberculosis that are associated with drug resistance result in the alteration of the 
phenotype due to changes in drug-bacterial interactions, including protein stability and/or structural changes 
that interfere with the mechanism of drug action. Detailed insights into mechanisms of drug-resistance muta-
tions can help in the design of new and improved existing drugs, the selection of improved drug targets and even 
identification of new drug targets. Because elucidating the effects of mutations experimentally is expensive and 
time consuming, many efforts have been made to develop computational methods that can predict the effects 
of mutations. These can be trained either using protein sequences alone or by taking structural features of the 
proteins into account. The most commonly used sequence-based methods such as SIFT24 and PolyPhen25 make 
use of features such as sequence conservation, estimated from multiple sequence alignments derived from closely 
related sequences, to predict the effects of mutations on protein function, while the structure-based methods 
benefit from the use of extensive structural parameters from the available 3D structures of proteins. Some of the 
well-established structure-based prediction programs include PoP-MuSiC26, BeAtMuSiC27, Site-Directed Mutator 
(SDM)28–30 and mutation Cut-off Scanning Matrix (mCSM)31–33.
SDM uses a statistical approach to predict the effects of mutations on protein stability and is based on the 
analysis of naturally occurring amino-acid substitutions expressed in the form of environment-specific substi-
tution tables (ESSTs). SDM calculates a stability score, which is analogous to the free-energy difference between 
the wildtype and the mutant protein. mCSM is based on a machine-learning approach and uses graph-based 
signatures to predict the effects of mutations on protein stability. mCSM has been trained to predict the effects of 
mutations on protein stability (mCSM-stability), protein-protein interactions (mCSM-PPI), protein-ligand affin-
ity (mCSM-lig) and protein-nucleic acid affinity (mCSM-NA). Our group has also developed tools, Intermezzo 
(Ochoa B. and Blundell T.L., unpublished) and Arpeggio34, to visualise the interactions of small-molecule drug 
binding; these go beyond hydrogen bonds and lipophilic interactions to include directional pi–pi and other inter-
actions of aromatic groups, as well as interactions mediated by drugs containing halogens. These programs have 
already been used by our group and others to generate insights into mutations in many genetic diseases, including 
cancer35,36.
In this study, we discuss the genome sequences of 98 M. tuberculosis isolates from Chennai in India. We define 
the population structure and map mutations onto the structures of their drug targets (katG, inhA and rpoB). The 
impacts of these mutations on protein structure stability, protein-protein and protein-ligand interactions are 
predicted using SDM and mCSM.
Results
Lineage diversity and phenotypic resistance. An SNP-based phylogenetic tree was constructed based 
on the sequence data of the 98 study isolates. This demonstrated that lineage 1 (Indo-Oceanic lineage) predomi-
nated (66, 67%), with the remainder falling into lineages 2 (9, 9%), 3 (9, 9%) and 4 (14, 15%) (Fig. 1). Phenotypic 
drug resistance to INH and RIF was mapped across these 98 isolates. Thirty-four and 24 isolates were resistant 
to INH and RIF, respectively. Resistant isolates were present across all four lineages (Fig. 1). All INH-resistant 
isolates in lineage 2 were also resistant to RIF, while isolates in other lineages (seven in lineage 1, two in lineage 3 
and four in case of lineage 4) were INH resistant but RIF susceptible.
Genetic determinants of resistance. The genetic basis for INH resistance was determined through an 
analysis of resistance-conferring mutations in katG, fabG1 promoter region and inhA. Thirty-three of the 34 resist-
ant isolates had known resistance mutations either in katG and/or fabG1 promoter or both. The remaining isolate 
had no known resistance-conferring mutation in katG or fabG1 promoter, but a stop-codon mutation was noted 
at the 575th codon in katG that resulted in premature termination and hence protein truncation, which might lead 
to the resistant phenotype. The S315 T mutation in katG and C-15T mutation in fabG1 promoter region were the 
most common mutations in resistant isolates, with frequencies of (23/34) 67.6% and (5/34) 14.7%, respectively 
(Fig. 2). Together, these two mutations accounted for 82% of INH resistance, which is concordant with previous 
reports37,38. We noted several other known mutations in katG and inhA in a minority of INH-resistant isolates 
(Table 1). One INH-resistant isolate possessed both S315T katG and C-15T fabG1 mutations. Resistant isolates 
have been reported previously to acquire multiple mutations in the same resistance-causing gene39. Five of the 
INH-resistant isolates had two mutations while one isolate had three mutations in katG.
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The genetic basis for RIF resistance was determined through an analysis of resistance-conferring mutations 
in rpoB40. Twenty-two isolates (92%) contained known resistance-conferring mutations in rpoB (Table 2). S450L 
and H445Y were the most frequent of these, with a frequency of 52% and 26%, respectively (Fig. 2). For the 
remaining two isolates where no resistance conferring mutations were identified, one isolate had a deletion in the 
RRDR (Rifampicin-resistance determining region), which is known to confer resistance41, but the other isolate 
had wildtype rpoB. Several other known rpoB mutations for RIF resistance were present at low frequency among 
Figure 1. Whole genome SNP based phylogenetic of 98 isolates. The circles 1 and 2 starting from inside out 
represent resistance and susceptibility to INH and RIF, respectively.
Figure 2. Frequency of resistance mutations identified in 98 isolates. The colours show phenotypic results for 
(A) isoniazid and (B) rifampicin.
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the RIF resistant isolates (Table 2). Compensatory mutations have been reported to occur in rpoC (23208709), 
which were also identified in a fraction of RIF-resistant isolates (Table 2).
Modelling mutations in katG. katG, a heme-dependent enzyme with dual catalase and peroxidase activity, 
is involved in the activation of the pro-drug, isoniazid42. The mutations listed in the Table 1 were mapped on the 
crystal structure of katG (PDB ID: 1SJ2) to visualize their locations on the protein (Supplementary Fig. S1). This 
showed that mutations were located in the N-terminal domain of the protein near the heme group. The effects of 
mutations on protein stability were predicted by SDM and mCSM (Table 3).
S315T, S315I, and S315N. The residue S315 is located at the narrowest edge of a substrate access channel that 
connects heme to the molecular surface (Fig. 3A). The substitution of serine to a bulkier sidechain threonine 
(Fig. 3B) has been described previously to constrict the channel and limit accessibility to heme23,43. Other sub-
stitutions of serine to isoleucine and asparagine, reported previously, were present in our clinical isolates. We 
predicted the effects of these mutations using SDM and mCSM and analysed the interatomic interactions of the 
wildtype and the mutant residues using intermezzo. The sidechain of the wildtype residue S315 was observed to 
form a hydrogen bond with the mainchain of I317 and a weak hydrogen bond with the heme and the sidechain 
of I317 (Fig. 3A). When mutated to threonine, the sidechain gains a weak hydrogen bond and hydrophobic inter-
actions with heme (Fig. 3B). The substitution of S315 to asparagine results in the loss of a hydrogen bond with 
I317 and a weak hydrogen bond with the heme (Fig. 3C). When mutated to isoleucine, the mutated residue loses 
both the hydrogen bond and the weak hydrogen bond with I317 and gains hydrophobic interactions with heme 
(Fig. 3D). Hence, substitution of S315 by other residues results in weaker affinity of katG towards heme.
W300G. The wildtype residue W300 makes carbon-pi interactions with A139, E287 and P288 and donor-pi 
interactions with A139 (Fig. 4A). It makes hydrophobic contacts with A139, E287, P288 and V284 and is involved 
Drug Gene Mutation Frequency
ISONIAZID
katG
S/315/T 23
S/315/N 2
S/315/I 1
W/300/G 1
S/575/Stop 1
In-del 1
fabG1
C/-15/T 5
T/-8/A 1
T/-8/C 1
G/-17/T 1
inhA
I/194/T 3
I/21/T 1
S/94/A 1
Table 1. Mutations identified in phenotypically isoniazid resistant strains.
Drug Gene Mutation (codon change) Frequency
RIFAMPICIN
rpoB
S/450/L (TCG/TTG) 12
D/435/Y (GAC/TAC) 1
D/435/V (GAC/GTC) 2
H/445/R (CAC/CGC) 1
H/445/Y (CAC/TAC) 5
S/428/R (AGC/AGG) 1
V/359/A (GTG/GCG) 2
S/441/P (TCG/CCG) 1
L/452/P (CTG/CCG) 2
L/449/Q (CTG/CAG) 1
In-del 1
rpoC
L/516/P (CTG/CCG) 1
V/483/G (GTG/GGG) 2
I/491/T (ATC/ACC) 1
N/416/T (AAC/ACC) 1
Table 2. Mutations identified in phenotypically rifampicin resistant strains.
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in forming weak hydrogen bonds with D142 and N133. The substitution of tryptophan by glycine causes the loss 
of all the interactions made by the wildtype residue (Fig. 4B).
Overall, the mutations in katG are predicted to be slightly destabilising or near neutral which implies that they 
do not come with a greater fitness cost for the protein. It is very likely the mutations in katG interfere with the 
drug binding of the protein.
Modelling mutations in inhA. We mapped the INH-resistance mutations identified onto the homo 
tetramer structure of inhA (PDB ID: 1ZID) (Supplementary Fig. S2). The mutations were found to be located 
around the drug-binding pocket (the drug INH is shown in yellow, Supplementary Fig. S2). The effects of muta-
tions on protein stability and ligand affinity were predicted using SDM, mCSM and mCSM-lig, respectively. The 
predictions made by the two programs are given in Table 3. These mutations are predicted to decrease the affinity 
of the drug towards the protein, hence resulting in a drug resistance phenotype.
I194T and 121T. The wildtype residue I194T is also present close to the INH-NAD-adduct binding site and 
is observed to form hydrophobic contacts with T196 and W230. The substitution of isoleucine by residues with 
shorter and polar sidechains results in the loss of hydrophobic interactions with W230 and hence decrease 
of the affinity of INH binding to inhA (Supplementary Fig. S3A,B). I194T is also reported to be present in 
ethionamide-resistant strains44. The wildtype residue I21 is present close to the INH-NAD adduct binding pocket 
and is involved in making hydrophobic contacts with M147 and V238. The substitution of isoleucine to a polar 
residue threonine results in the loss of these hydrophobic interactions and hence affects the binding of INH-NAD 
adduct to inhA (Supplementary Fig. S3C,D).
rpoB subunit of RNA polymerase. rpoB is the β subunit of the bacterial RNA polymerase, which is tar-
geted by the first-line anti-tuberculosis drug, rifampicin. Resistance to rifampicin is caused by the mutations in 
the binding pocket of the drug. The effects of mutations were predicted using SDM2 and mCSM and the intera-
tomic interactions analysed by Intermezzo. Whereas a previously reported analysis23 was based on a homology 
model, we were able to analyse the impacts of the mutations in the rpoB and rpoC subunits of the RNA polymer-
ase using a recently defined crystal structure (PDB ID: 5UHC)45 mapped onto the highly conserved drug binding 
pocket (Supplementary Fig. S4 and Fig. 5A).
S450L. S450L is one of the most frequently occurring RFP-resistant mutations46,47. It is predicted to decrease 
the affinity of the drug towards the protein by mCSM-lig. Evaluation of interatomic interactions of the wildtype 
and the mutant residue using Intermezzo showed that the wildtype residue S450 forms a hydrogen bond with 
rifampicin (Fig. 5B) but when it is mutated to leucine, the longer sidechain causes steric clashes with the drug 
(Fig. 5C), reducing its affinity towards the drug as indicated by mCSM-lig value (Table 3).
Target Mutation
Predicted 
ΔΔG
SDM2
Predicted 
ΔΔG
mCSM
Predicted 
Affinity 
Change
mCSM-
lig
Predicted 
ΔΔG
mCSM-
PPI
katG
S315T 0.34 −0.33 −0.065
S315I 0.25 −0.424 0.06
S315N −0.02 −0.184 −0.203
A106V −1.14 −0.234 −1.625
W300G 0.42 −3.804 −0.521
inhA
S94A 0.36 −0.89 −0.485 −0.14
I194T −2.42 −2.347 −1.603 −0.423
I21T −1.06 −1.84 −1.679 −0.107
rpoB
S450L 0.14 −0.152 −0.234 −0.215
H445R −1.18 −1.583 −0.633 −1.362
H445Y −0.43 −0.075 −0.173 −0.157
D435Y −0.71 0.042 −0.138 −0.294
D435V 0.33 1.513 −0.193 0.155
L452P 0.58 −0.982 −1.007 −0.018
V359A −2.36 −1.849 −0.256 −0.426
S428R 0.26 −0.356 −0.736 −0.203
rpoC
L516P −3.918 −1.48 −0.401
N416T −0.06 −0.194 −1.086
V483G −2.72 −3.134 −0.594
I491T −1.51 −2.803 −0.464
Table 3. Predicted effects of mutations in katG, inhA, rpoC and rpoB on protein stability (using SDM2, 
mCSM), protein-protein interactions (using mCSM-PPI) and protein-ligand interactions (using mCSM-lig). 
All ΔΔG values are in kcal/mol.
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Figure 3. (A) The wildtype residue S315 of katG forms a hydrogen bond (shown as red dotted lines) with the 
main chain of I317 and a weak hydrogen bond (orange dotted lines) with heme and sidechain of I317. (B) The 
mutant residue T315 gains an additional weak hydrogen bond and hydrophobic interactions with heme. (C) The 
mutant residue loses the hydrogen bond with I317 and a weak hydrogen bond with heme. (D) The hydrophobic 
sidechain of isoleucine retains the weak hydrogen bond with RFP and gains hydrophobic interaction with heme.
Figure 4. (A) The katG wildtype residue W300 is involved in the formation of carbon-pi interactions with 
A139, E287 and P288 and donor-pi interactions with A139. All the atom-pi interactions are shown as purple 
dotted lines. It also forms weak hydrogen bonds with N133 and D142 indicated as orange dotted lines. (B) The 
mutant residue G300 loses all the interactions with the surrounding residues.
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H445R and H445Y. H445R was observed to be present in the RFP-binding pocket and the interatomic anal-
ysis using Intermezzo revealed that this mutation affects the interactions with the surrounding residues 
(Supplementary Fig. S5A). The wildtype residue forms hydrophobic interactions with D435, which are involved 
in forming hydrophobic interactions with RFP, while the mutant residue R445 causes steric clashes with D435 
(Supplementary Fig. S5B). The wildtype histidine also forms carbon-pi contacts with V168 and R448 and 
cation-pi contacts with R448, which are lost for the mutant R445 and Y445. The mutant residue Y445 gains the 
carbon-pi and cation-pi contacts with D435 (Supplementary Fig. S5C).
D435Y and D435V. The wildtype residue D435 is located within 3.1 Å and forms a salt bridge with R448 and 
R607 (Fig. 6A). It also forms a weak hydrogen bond with R607 and rifampicin, and hydrophobic interactions with 
H445 and rifampicin. The substitution of aspartic acid to valine causes the loss of ionic interactions with R448 and 
R607 (Fig. 6B). The mutated residue also loses its weak hydrogen bond with rifampicin. The mutation of aspartic 
acid to tyrosine introduces a steric clash between the tyrosine sidechain and the drug (Fig. 6C,D), leading to the 
decreased affinity of the drug towards the protein as indicated by mCSM-lig values (Table 3). Other mutations 
were also observed to alter the interactions with the drug as in L452P (Supplementary Fig. S6) and with the sur-
rounding residues in the case, V359A (Supplementary Fig. S7), and S428R (Supplementary Fig. S8).
rpoC subunit of RNA polymerase. We observed four mutations in the rpoC subunit in response to 
rifampin (I491T, L516P, N416T, V483G), which are present at the interfaces with other subunits in the RNA 
polymerase assembly (Supplementary Fig. S9). The mutations L516P, I491T and V483G are in close proximity 
with the subunits rpoA and rpoZ, while the mutation N416T is located at the interface with the subunit rpoB. The 
effects of these mutations on protein-protein interactions were predicted using mCSM-PPI (Table 3).
The wildtype residue I491 is involved in making hydrophobic contacts with L487, L516, P514 and F452 
(Fig. 7A). It also forms a carbon-pi contact with F452 and weak hydrogen bonds with the carbonyl oxygen of the 
residues P514 and L487. When mutated to threonine, the carbon-pi and hydrophobic contacts are lost. Moreover, 
the mutated residue loses the weak hydrogen bond with L487 and gains a weak hydrogen bond with the main-
chain carbonyl oxygen of E488 (Fig. 7B). It also loses the weak hydrogen bond with the carbonyl oxygen of P514 
and instead gains a weak hydrogen bond with the sidechain carbon CG of the P514. The wildtype residue L516 
is involved in making hydrophobic contacts with I491, L487 and E488. When mutated to proline, the bulkier 
sidechain of proline causes a steric clash with I491 (Supplementary Fig. S10). For N416T, the wildtype aspar-
agine forms a hydrogen bond and a weak hydrogen bond with R412 but when mutated to threonine it gains an 
additional hydrogen bond with R412. Threonine also gains a weak hydrogen bond with S1120 and hydrophobic 
Figure 5. (A) Mutations mapped on the crystal structure of rpoB. Mutations mapped in green spheres are 
located in the rifampicin (cyan spheres) binding pocket. (B) The wildtype residue S450 (green) forms hydrogen 
bond (shown in red dotted lines) with RFP. (C) The bulkier sidechain of mutant L450 causes steric clashes with 
RFP.
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Figure 6. (A) The wildtype residue D435 in rpoB forms salt bridges with R448 and R607 (blue dotted lines), 
weak hydrogen bonds (orange dotted lines) with R607 and RFP and hydrophobic interactions with RFP and 
H445. (B) The mutant V435 loses the ionic interactions and the weak hydrogen bonds. (C) The mutated residue 
Y435 causes steric clashes with RFP. (D) Spheres representation of the steric clash between Y435 and RFP.
Figure 7. (A) The rpoC wildtype residue I491 makes a carbon-pi interaction with F452. It also forms a weak 
hydrogen bond with the backbone of L487 and another weak hydrogen bond with the carbonyl oxygen of P514. 
(B) The mutated residue loses the carbon-pi interaction with F452 and makes a weak hydrogen bond with the 
sidechain CG of the residue P514 and another weak hydrogen bond with the backbone of E488.
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interactions with T1053 from chain C (Supplementary Fig. S11). The wildtype residue V483 is involved in mak-
ing hydrophobic contacts with W484, L449, V476 and L460, and makes a carbon-pi contact with W484. When 
mutated to glycine, it loses all the interactions with the surrounding residues (Supplementary Fig. S12).
Most of the mutations in inhA and rpoB affect both the stability and the drug-binding affinity of the protein. 
The mutations in rpoC are predicted to have an impact on both protein stability and protein-protein interactions.
Discussion
Early detection of drug-resistant M. tuberculosis is key to rapid, effective patient treatment and reduction in 
ongoing transmission. Whole genome sequencing offers the potential to detect genetic mutations associated with 
phenotypic resistance at an earlier timepoint than culture-based methods, but the majority of M. tuberculosis 
genomes on which predictions are based belong to the globally dominant lineages 2 and 4. More studies are 
needed from regions where other lineages predominate, including in India where lineage 1 and 3 prevail. Here, 
we report the results of a study of whole genome sequencing of M. tuberculosis from Southern India, in which 
phenotypic DST was compared with sequence-based predictions to understand the frequency of already known 
and putative resistance-conferring mutations in this population. Our genome analysis and identification of previ-
ously known mutations conferring resistance to INH and RIF were extended by in silico analyses to gain insights 
into drug resistance mechanisms by mapping mutations onto the protein structure.
Lineage 1 was dominant in our collection, which is consistent with previous reports from the region (Singh et 
al. 2015). As katG is required for the activation of INH, mutations in katG are likely to be a first step in acquiring 
drug resistance and most mutations leading to resistance to INH are reported to be present in katG. The substi-
tution S315T found here is the most frequent isoniazid-resistant mutation in several studies48–50. This has also 
been reported experimentally to be sufficient alone to confer resistance to INH51 and decrease the affinity of INH 
towards the protein52.
S94A substitution in inhA is a frequently reported mutation and has been well characterised in the litera-
ture. The analysis of the crystal structure of the mutant S94A by various groups53–55 indicates that the resistance 
mutation causes a reduced affinity of NADH binding to inhA, by disrupting the hydrogen-bonding network of a 
conserved water molecule in the active site by mutating the polar residue serine to the non-polar residue, alanine. 
These studies suggest that NADH binding is a pre-requisite for NAD-INH adduct formation and a decrease in 
binding affinity of NADH in mutants leads to drug resistance53. Furthermore, thermodynamic studies56 suggested 
no significant change in the adduct binding affinity to wildtype and mutant enzymes and they proposed that the 
resistance might be due to allosteric effects caused by the interaction of other proteins with inhA within the FAS 
II pathway. They also presented evidence to suggest that NAD-INH adduct forms in solution and the decrease in 
NADH affinity does not significantly alter the NAD-INH affinity for the enzyme56.
Drug-resistant mutations in rpoB have mostly been found in the 81-bp region of rpoB, sometimes called the 
Rifampicin Resistance Determining region (RRDR)57. Many mutations in rpoB occur in the highly conserved res-
idues in the drug-binding pocket. These mutations in rpoB come with a fitness cost, while mutations in rpoC are 
proposed to compensate for this fitness cost58. de Vos et al. reported the presence of putative compensatory rpoC 
mutations in 23.5% of all rifampicin resistant isolates and these were associated with specific strain genotypes and 
specific rpoB mutation (S531L) as 44.1% of isolates with this mutation also harboured rpoC mutations59. A more 
recent study by Yun et al. (2018) reported the presence of rpoC mutations in 25.8% of the total isolates60. In our 
study, we found that 8/24 resistant isolates had mutations in rpoC, of which 7 had the S450L dominant mutation. 
This concurs with a previous study linking the dominant mutation with the acquisition of potential compensatory 
mutations. Moreover, the mutations in rpoC were found to be located at the interfaces with other subunits, as 
reported in earlier studies58,59.
An interesting observation from our study is that both the mutations S450L in rpoB and S315T in katG that 
dominated resistant isolates at no/low fitness cost61–63 are also predicted to have a near neutral effect on protein 
stability and/or ligand binding affinity (Table 3). This also supports the observation that frequency of occurrence 
of a drug-resistant mutation inversely correlates with fitness cost64.
Computational approaches such as ours for elucidating the effects of mutations are useful for the rapid analysis 
of a large dataset of mutations as experimental approaches may be time consuming and expensive. This analysis 
should be useful in understanding the mechanism of drug resistance in tuberculosis.
Methods
Bacterial isolates. The 98 M. tuberculosis isolates included here were from patients recruited at the 
Government Hospital for Thoracic Medicine, Chennai, India. Patients were diagnosed and treated under India’s 
RNTCP (Revised National Tuberculosis Control Program). Two cohorts were recruited, as follows:
 (i) Cohort 1 (drug resistant tuberculosis) comprised adults with newly diagnosed drug resistant pulmonary 
TB (PTB), who were given RNTCP Category IV treatment (either LPA positive for RIF resistant M. tuber-
culosis or GeneXpert positive with Rifampicin resistance at entry)
 (ii) Cohort 2 (drug sensitive tuberculosis) comprised adults with newly diagnosed active PTB, who were 
given RNTCP Category I treatment (sputum smear positive for acid fast bacilli or GeneXpert positive with 
Rifampicin sensitive at entry)
The following lists the inclusion criteria for the patients in the study:
 1. New sputum-smear-positive drug-sensitive pulmonary TB patients who have not received or have received 
less than 10 days of anti-TB treatment (OR) sputum smear positive drug resistant pulmonary TB patients 
who have not received or have received less than a month of second line anti-TB treatment.
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 2. Age more than 18 yrs.
 3. Body weight more than 30 kgs.
 4. Residing within the selected TU areas.
 5. Willing for study procedures, including home visits.
 6. Willing to give written informed consent.
All the procedures were conducted following the guidelines of the Institutional Ethical Committee of Indian 
Council of Medical Research-National Institute for Research in Tuberculosis (ICMR-NIRT), Institutional Ethics 
Committee (IEC) No: 2016002(A). Informed and written consent for participation was obtained from all the 
participants involved in the study following the ethical guidelines before enrolling in the study. All the exper-
iments conducted in the study were approved by the institutional ethical committee of ICMR-NIRT, IEC No: 
2016002(A).
Phenotypic drug susceptibility testing (DST). Sputum samples were processed using sodium hydroxide 
and N-acetyl-l-cysteine (NaOH-NALC) followed by inoculating 0.5 ml of the processed specimen into a MGIT 
tube containing 7 ml of 7H9 broth with 0.8 ml of growth supplement (OADC-PANTA). MGIT tubes were then 
placed in the MGIT960 instrument until bottles flagged positive [10 υ − 10 ϖ colony forming units (CFU) per ml 
of medium]. Positive cultures were evaluated for contamination by inoculating a loop onto Brain Heart Infusion 
Agar plate and incubated at 37 °C for 48 hrs.
The immune chromatographic test (MPT64- protein Specific detection) for MTBC65 was used to confirm M. 
tuberculosis. Each of the positive cultures was then subjected to DST for Isoniazid (INH) and Rifampicin (RIF). 
To perform DST, three sets of MGIT tubes for each positive culture were used (growth control (drug free), con-
taining Isoniazid (INH) at 0.1 µg/ml, and Rifampicin (RIF)1.0 µg/ml plus growth supplement66. All tubes were 
placed into MGIT960 instrument. Predefined algorithms of growth units between drug-free tubes (GC) and 
drug-containing tubes were compared by the MGIT960 system software. After 14 days, if the relative growth of 
the drug containing tube was less than the GC, the culture was declared as drug susceptible and if equal or exceed-
ing GC, it was considered as drug resistant.
DNA extraction
M. tuberculosis cultured on LJ medium was transferred into 1.8-ml screw-cap tubes containing ∼500 μl of 
TE buffer and genomic DNA extracted using the cetyltrimethyl ammonium bromide (CTAB)–NaCl extrac-
tion method, as described previously67. DNA purification was performed using Genomic DNA Clean and 
Concentrator kit (Zymo Research) according to the manufacturer’s instruction.
Sequencing and genome analysis
DNA libraries were prepared using the NexteraXT DNA Library preparation kit (Illumina), according to the 
manufacturer’s instruction. Normalization of libraries was achieved by manual normalization method using ana-
lyzed library size in Bioanalyzer (Agilent), and the library quantity was measured in Qubit (Thermo Scientific). 
Whole genome sequencing of the 98 isolates was carried out on Illumina MiSeq instrument using the Miseq 
Reagent kit v3. Raw sequence reads were filtered using Trimmomatic (version 0.36) with parameters of min-
imum base quality and read length set to 20 and 30% of the read length68. Filtered reads were mapped to the 
reference genome H37Rv (NC_000916.3) using the Burrows-Wheeler Aligner69 (version 0.7.12) using the default 
parameters. The alignment was then corrected for InDels using picard (version 2.2.4) and GATK (version 3.5)70. 
Variants were identified using samtools (version 1.3.1) [4] and bcftools (version 1.3.1). Those variants with base 
quality > 50, mapping quality > 30, depth greater than 5 and at least one read in either direction were identified 
as high-quality variants using an in-house python script. Variants were compared against a database of mutations 
created by combining those reported by Bradley P et al.11, PhyResSE15 (as on Aug, 2016), Coll F et al.12, Farhat MR 
et al.14 and Desjardins CA et al.13 using an in-house python script. Lineages were identified based on a combina-
tion of lineage-defining single nucleotide polymorphisms (SNPs) reported by Coll F et al.37 and RD-analyzer38 
that relies on the presence or absence of regions of difference specific to lineages of M. tuberculosis. To con-
struct the phylogenetic tree, a pseudogenome was generated after replacing the reference base with the alternate 
allele identified above. Repetitive regions as reported by Holt et al.71 were masked using bedtools72 (v2.27.1). 
Pseudogenomes were used as input for SNP-Sites73 (Andrew J Page, et al., 2016, microbial genomics) to identify 
variable sites among the genomes. The output was then used to generate a phylogenetic tree using RAxML74 with 
GTR-GAMMA model with 1000 bootstrap replications.
Mutation mapping, modelling and prediction of effects on katG, inhA and rpoB. Mutations 
identified from the sequence data were mapped on the crystal structures of katG (PDB ID 1SJ2), rpoB and rpoC 
(PDB ID 5UHC) using pyMol and the mutant models were generated using Modeller75. The web server of the 
recently updated version of SDM (Pandurangan et al. 2017; Worth et al. 2011; Topham et al. 1997), available at 
http://marid.bioc.cam.ac.uk/sdm2/ was used to predict the effects of mutations on protein structure stability. PDB 
files of the protein structures and text files containing the sets of mutations were provided as input to the server 
to estimate the change in free energy (ΔΔG) between the wild and mutant forms of the proteins. mCSM was 
used to investigate the effects of drug resistance mutations on protein-structure stability (http://biosig.unimelb.
edu.au/mcsm/stability), protein-protein interface stability (mCSM-PPI, available at http://biosig.unimelb.edu.
au/mcsm/protein_protein), and drug affinity binding using mCSM-lig (available at http://biosig.unimelb.edu.
au/mcsm_lig/). PDB files of protein structures and text files containing sets of mutations were provided as inputs 
to the server. The PyMOL plugin Intermezzo (Ochoa et al., unpublished) (http://mordred.bioc.cam.ac.uk/inter-
mezzo/) was used to calculate and visualize interatomic interactions.
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Data Availability
All sequences from this study have been submitted to the NCBI, Bioproject (Bioproject; https://www.ncbi.nlm.
nih.gov/bioproject) under the accession PRJNA512266 and individual accession numbers for the Sequence Read 
Archive are given in Supplementary Table S1.
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